Antithrombotic agents

• US 4,210,670 A
• Filed: 06/23/1978
• Issued: 07/01/1980
• Est. Priority Date: 07/06/1977
• Status: Expired due to Term

• Current Assignee: Astra Laekemedel AB
• Original Assignee: Astra Laekemedel AB
• Inventors: Cooke, Ernest
• Primary Examiner(s): Friedman, Stanley J.
• Application Number:
  US05/918,476
• Time in Patent Office: 739 Days
• Field of Search: 424/324
• US Class Current: 514/626
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine

Abstract

The invention relates to a method for prophylactic treatment in order to eliminate the formation of tromboses and embolis in deep veins after surgical incisions in lower body regions, whereby a local anesthetic compound of the group consisting of lidocaine, mepivacaine, bupivacaine, tocainide, prilocaine, and ethidocaine is administered, as well as pharmaceutical preparations herefore.

Claims

1. A method for prophylactic prevention of postoperative deep venous thrombosis in mammals, including man, which are to be subjected to surgical incisions, whereby a therapeutically effective amount of a compound selected from the group consisting of 2-amino-2'"'"',6'"'"'-propionoxylidide and diethylaminoacet-2'"'"',6'"'"'-xylidide, or a therapeutically acceptable salt thereof is administered.

2. A method according to claim 1, wherein the therapeutic agent is administered intravenously.

3. A method according to claim 2 wherein the therapeutic agent is administered continuously at a rate of 2 mg/minute from 2 hrs pre surgery and to 144 hrs post surgery.

4. A method according to claim 2 wherein the therapeutic agent is administered as an intravenous bolus administration of 1 mg per kg bodyweight 2 hrs pre surgery, followed by a continuous intravenous administration of 2 mg/minute from 2 hrs pre surgery to 144 hrs post surgery.

5. A method according to claim 4, wherein the bolus administration is carried out using a 2% solution of the therapeutic agent.

6. A method according to claim 2, wherein the continuous intravenous administration is carried out having the therapeutic agent dissolved in a 5% dextrose solution.

7. A method according to claim 1, wherein 2-amino-2'"'"',6'"'"'-propionoxylidide is administered orally.